AM1187 AM1187
LB77 LB77
MLU - 04/25/2025 MLU - 04/25/2025
AMENDMENTS TO LB77
Introduced by Banking, Commerce and Insurance.
1 1. Strike the original sections and insert the following new
2 sections:
3 Section 1. Sections 1 to 13 of this act shall be known and may be
4 cited as the Ensuring Transparency in Prior Authorization Act.
5 Sec. 2. For purposes of the Ensuring Transparency in Prior
6 Authorization Act, unless the context otherwise requires:
7 (1) Adverse determination has the same meaning as in section
8 44-1303;
9 (2) Clinical peer means a health care provider in the same, or in a
10 similar, specialty that typically manages the medical condition or health
11 care service under review;
12 (3) Clinical review criteria has the same meaning as in section
13 44-1303;
14 (4) Department means the Department of Insurance;
15 (5) Emergency health care services means health care services
16 medically necessary to screen and stabilize a patient in connection with
17 an emergency medical condition until the health care provider determines
18 such individual is able to travel using nonmedical transportation;
19 (6) Emergency medical condition has the same meaning as in section
20 44-1303;
21 (7) Enrollee means an individual who is enrolled in a health benefit
22 plan, including covered dependents;
23 (8) General acute hospital has the same meaning as in section
24 71-412;
25 (9) Health benefit plan has the same meaning as in section 44-1303;
26 (10) Health care provider has the same meaning as in section
27 44-1303;
-1-

AM1187 AM1187
LB77 LB77
MLU - 04/25/2025 MLU - 04/25/2025
1 (11) Health care services has the same meaning as in section
2 44-1303;
3 (12) Health carrier has the same meaning as in section 44-1303,
4 except that health carrier does not include a managed care agent;
5 (13) Medically necessary has the same meaning as in section 44-6845;
6 (14) Notice means communication delivered either electronically or
7 through the United States Postal Service or a common carrier;
8 (15) Physician means an individual licensed under the Medicine and
9 Surgery Practice Act to practice medicine and surgery or osteopathic
10 medicine and surgery or an individual with an equivalent license from
11 another United States jurisdiction;
12 (16) Prior authorization means the process by which a health carrier
13 or utilization review agent makes a determination that a requested
14 admission, extension of stay, or health care service has been reviewed
15 and, based on the information provided, satisfies the health carrier's or
16 utilization review agent's requirements for reimbursement under the
17 applicable health benefit plan;
18 (17) Urgent health care service means a health care service with
19 respect to which the application of the time periods prescribed under the
20 Ensuring Transparency in Prior Authorization Act for making a
21 nonexpedited prior authorization could, in the opinion of a physician
22 with knowledge of the enrollee's medical condition:
23 (a) Seriously jeopardize the life or health of the enrollee or the
24 ability of the enrollee to regain maximum function; or
25 (b) Subject the enrollee to severe pain that cannot be adequately
26 managed without the care or treatment that is the subject of the
27 utilization review; and
28 (18) Utilization review agent has the same meaning as in section
29 44-5418.
30 Sec. 3. (1) A utilization review agent shall make prior
31 authorization requirements and restrictions, including written clinical
-2-

AM1187 AM1187
LB77 LB77
MLU - 04/25/2025 MLU - 04/25/2025
1 review criteria, accessible on its website. Such requirements,
2 restrictions, and clinical review criteria shall be accurate and current
3 and shall clearly communicate what information and documentation is
4 needed to decide the prior authorization. Prior authorization
5 requirements shall also be made available on the website in a searchable
6 format no later than July 1, 2027.
7 (2) If a utilization review agent intends either to implement a new
8 prior authorization requirement or restriction or to amend an existing
9 requirement or restriction, the utilization review agent shall:
10 (a) Ensure that the new or amended requirement or restriction is not
11 implemented unless the utilization review agent's website has been
12 updated to reflect the new or amended requirement or restriction; and
13 (b) Provide contracted health care providers with notice of the new
14 or amended requirement or restriction no less than sixty days before the
15 requirement or restriction is implemented.
16 Sec. 4. (1) A utilization review agent shall ensure that all
17 adverse determinations for prior authorization are made by a physician,
18 except that if the requesting health care provider is not a physician,
19 the adverse determination may be made by a clinical peer of the
20 requesting health care provider. Such physician or clinical peer shall:
21 (a) Possess a current and valid nonrestricted license in a United
22 States jurisdiction;
23 (b) Have the appropriate training, knowledge, or expertise to apply
24 appropriate clinical guidelines to the health care service being
25 requested; and
26 (c) Make the adverse determination under the clinical direction of
27 one of the utilization review agent's medical directors who is
28 responsible for the provision of health care services provided to
29 enrollees of Nebraska. All such medical directors must be physicians
30 licensed in a United States jurisdiction.
31 (2) When an adverse determination for prior authorization is issued
-3-

AM1187 AM1187
LB77 LB77
MLU - 04/25/2025 MLU - 04/25/2025
1 or a prior authorization is canceled or voided, the utilization review
2 agent shall provide notice to the requesting health care provider. The
3 notice shall include the reason for denial, citing written clinical
4 review criteria.
5 (3)(a) If an adverse determination for prior authorization questions
6 the medical necessity, the appropriateness, or the experimental or
7 investigational nature of a health care service, the enrollee's health
8 care provider shall have the opportunity to discuss the health care
9 service with the physician or clinical peer who is responsible for
10 determining authorization of the health care service under review. The
11 enrollee's health care provider may request that such discussion occur
12 within three business days after receiving notice of the adverse
13 determination. No discussion shall be required or allowed for an adverse
14 determination that is due to contract exclusions or benefits that are not
15 covered by the health benefit plan.
16 (b) Following any discussion under subdivision (3)(a) of this
17 section, the utilization review agent shall notify the requesting health
18 care provider whether the adverse determination decision remains the
19 same. The notice under this subdivision shall be provided (i) within one
20 business day after the discussion under subdivision (3)(a) of this
21 section for an urgent health care service or (ii) within two business
22 days after the discussion under subdivision (3)(a) of this section for a
23 nonurgent health care service.
24 (c) A discussion under subdivision (3)(a) of this section shall not
25 replace or eliminate the opportunity for any internal grievance or appeal
26 process provided by the utilization review agent.
27 Sec. 5. A utilization review agent shall ensure that all appeals of
28 an adverse determination for prior authorization are reviewed by a
29 physician. Such physician shall:
30 (1) Possess a current and valid unrestricted license in a United
31 States jurisdiction;
-4-

AM1187 AM1187
LB77 LB77
MLU - 04/25/2025 MLU - 04/25/2025
1 (2) Be of the same or similar specialty as the ordering physician or
2 have the training and experience to treat the condition, which means that
3 either:
4 (a) The physician maintains board certification for the same or
5 similar specialty; or
6 (b) The physician's training and experience (i) includes treating
7 the condition, (ii) includes treating complications that may result from
8 the health care service, and (iii) is sufficient for the physician to
9 determine based on the physician's clinical judgment whether the health
10 care service is medically necessary or clinically appropriate;
11 (3) Not have been directly involved in making the initial adverse
12 determination;
13 (4) Not have any financial interest in the outcome of the appeal;
14 and
15 (5) Consider all known clinical aspects of the health care service
16 under review, including, but not limited to, a review of those medical
17 records which are pertinent and relevant to the active condition provided
18 to the utilization review agent by the enrollee's health care provider,
19 or a health care facility, and any pertinent medical literature provided
20 to the utilization review agent by the health care provider.
21 Sec. 6. (1)(a) On or before November 1, 2025, the department shall
22 approve a single uniform prior authorization request form for
23 prescription drugs, devices, and durable medical equipment and a single
24 uniform prior authorization request form for all other health care
25 services. The uniform prior authorization request forms shall not exceed
26 two printed pages in length. This two-page limit does not apply to
27 information or documentation required by the utilization review agent, as
28 published in accordance with subsection (1) of section 3 of this act, or
29 a health care provider's notes or documentation submitted in support of a
30 prior authorization request.
31 (b) Beginning January 1, 2026:
-5-

AM1187 AM1187
LB77 LB77
MLU - 04/25/2025 MLU - 04/25/2025
1 (i) All health care providers shall use only the approved uniform
2 prior authorization request forms; and
3 (ii) Except as provided in subsection (2) of this section, all
4 utilization review agents shall accept and process prior authorization
5 requests submitted using such forms.
6 (c) This subsection does not prohibit a utilization review agent
7 from using a prior authorization methodology that uses an Internet
8 webpage, an Internet webpage portal, or a similar web-based system if the
9 methodology is consistent with the uniform prior authorization request
10 forms approved by the department pursuant to this subsection.
11 (2) A utilization review agent may request from the department an
12 exemption from the requirements of subsection (1) of this section if the
13 utilization review agent implements and maintains a prior authorization
14 application programming interface pursuant to 45 C.F.R. 156.223(b) or
15 other electronic prior authorization methodology that automates and
16 standardizes the prior authorization process for patients, health care
17 providers, and health carriers. A utilization review agent shall provide
18 notice to health care providers at least ninety days prior to
19 implementing a prior authorization application programming interface or
20 other electronic prior authorization methodology under this subsection.
21 Sec. 7. (1) Prior to January 1, 2028, if a utilization review agent
22 requires prior authorization of a health care service, the utilization
23 review agent shall make a decision on the prior authorization request and
24 provide notice of its decision to the enrollee and the enrollee's health
25 care provider in accordance with the following timeframes:
26 (a) For a prior authorization request for urgent health care
27 services, within seventy-two hours after obtaining all necessary
28 information to make a decision; or
29 (b) For a prior authorization request for nonurgent health care
30 services, within seven days after obtaining all necessary information to
31 make a decision.
-6-

AM1187 AM1187
LB77 LB77
MLU - 04/25/2025 MLU - 04/25/2025
1 (2) Beginning January 1, 2028, if a utilization review agent
2 requires prior authorization of a health care service, the utilization
3 review agent shall make a decision on the prior authorization request and
4 provide notice of its decision to the enrollee and the enrollee's health
5 care provider in accordance with the following timeframes:
6 (a) For a prior authorization request for urgent health care
7 services, within forty-eight hours after obtaining all necessary
8 information to make a decision; or
9 (b) For a prior authorization request for nonurgent health care
10 services, within seven days after obtaining all necessary information to
11 make a decision.
12 (3) Nothing in this section prohibits a health care provider and
13 health carrier from contracting for shorter timeframes for using the
14 prior authorization application programming interface or other electronic
15 prior authorization methodology described in subsection (2) of section 6
16 of this act or as part of a risk-sharing agreement.
17 (4) Health care services are deemed authorized if a utilization
18 review agent fails to comply with the deadlines for making a decision as
19 set forth in this section.
20 (5) In the notice to the health care provider that a prior
21 authorization has been approved, the utilization review agent shall
22 include the duration of the prior authorization or the date by which the
23 prior authorization will expire.
24 Sec. 8. No utilization review agent shall require prior
25 authorization of:
26 (1) Emergency confinement or an emergency health care service;
27 (2) Pre-hospital transportation for the provision of emergency
28 health care services or for transfers between facilities as required by
29 the federal Emergency Medical Treatment and Labor Act; or
30 (3) Services that have a rating of A or B from the United States
31 Preventive Services Task Force, immunizations recommended by the Advisory
-7-

AM1187 AM1187
LB77 LB77
MLU - 04/25/2025 MLU - 04/25/2025
1 Committee on Immunization Practices of the Centers for Disease Control
2 and Prevention, or preventive services and screenings provided to women
3 as required by 45 C.F.R. 147.130.
4 Sec. 9. (1) A utilization review agent shall not revoke, limit,
5 condition, or restrict an approved prior authorization if care is
6 provided within sixty days from the date the health care provider
7 received the prior authorization approval unless the enrollee was no
8 longer eligible for care on the day care was provided.
9 (2) A health carrier shall pay a contracted health care provider at
10 the contracted payment rate for a health care service provided by the
11 health care provider per an approved prior authorization request, unless:
12 (a) The health care provider knowingly and materially misrepresented
13 the health care service or patient's medical history in the prior
14 authorization request with the intent to deceive and obtain an unlawful
15 payment under the health benefit plan;
16 (b) The health care service was no longer a covered benefit on the
17 day it was provided;
18 (c) The health care provider was no longer contracted with the
19 patient's health benefit plan on the date the care was provided;
20 (d) The health care provider failed to meet the utilization review
21 agent's timely filing requirements;
22 (e) The patient was no longer eligible for health care coverage on
23 the day the care was provided; or
24 (f) The health care provider failed to obtain prior authorization
25 approval before rendering health care services for which prior
26 authorization was required.
27 Sec. 10. (1) Except as otherwise provided in this section, prior
28 authorization shall be valid for at least one year from the date the
29 utilization review agent approves the prior authorization request, except
30 for a prescription drug that has a treatment schedule or dosing
31 limitation from the federal Food and Drug Administration of less than one
-8-

AM1187 AM1187
LB77 LB77
MLU - 04/25/2025 MLU - 04/25/2025
1 year.
2 (2)(a) If a prior authorization is required for inpatient care at a
3 general acute hospital, the prior authorization shall remain valid for
4 the length of stay approved by the utilization review agent.
5 (b) If the health care provider submits a timely request for the
6 continuation of inpatient care, the utilization review agent shall
7 respond to this request prior to the expiration of the current
8 authorization for inpatient care.
9 (c) If a utilization review agent fails to respond to a timely
10 request for the continuation of inpatient care prior to the termination
11 of the previously approved length of stay, then the health carrier shall
12 continue to compensate the health care provider at the contracted rate
13 for inpatient care provided until the utilization review agent issues its
14 determination on the prior authorization request.
15 (d) Nothing in this subsection shall be interpreted to prohibit a
16 health care provider or enrollee from appealing an adverse determination
17 as allowed under state law. If an adverse determination is overturned on
18 appeal, and no other legal action related to the claim is pending, then
19 the health carrier shall reimburse the health care provider at the
20 contracted rate for inpatient care provided to the enrollee.
21 (3) This section does not require a health benefit plan to cover
22 care, treatment, or services for a health condition that the terms of
23 coverage otherwise completely exclude from the policy's covered benefits
24 without regard for whether the care, treatment, or services are medically
25 necessary.
26 Sec. 11. (1) On receipt of information documenting an approved
27 prior authorization from the enrollee or from the enrollee's health care
28 provider, a utilization review agent shall honor the approved prior
29 authorization granted to an enrollee from a previous utilization review
30 agent for at least the initial sixty days of an enrollee's coverage under
31 a new health benefit plan. During such time period, a utilization review
-9-

AM1187 AM1187
LB77 LB77
MLU - 04/25/2025 MLU - 04/25/2025
1 agent may perform its own review to grant a prior authorization.
2 (2) If there is a change in coverage of, or approval criteria for, a
3 previously authorized health care service, the change in coverage or
4 approval criteria does not affect a prior authorization request approved
5 before the effective date of the change.
6 (3) A utilization review agent shall continue to honor a prior
7 authorization it has granted to an enrollee when the enrollee changes
8 health insurance products under the same health insurance company without
9 any action required by the health care provider.
10 Sec. 12. (1) An artificial intelligence-based algorithm shall not
11 be the sole basis of a utilization review agent's decision to deny,
12 delay, or modify health care services based, in whole or in part, on
13 medical necessity.
14 (2) A utilization review agent shall disclose to the department, to
15 each health care provider in its network, to each enrollee, and on its
16 public website if artificial intelligence-based algorithms are used or
17 will be used in the utilization review process.
18 (3) The department may, at any time, audit a utilization review
19 agent's automated utilization management system. The department may
20 contract with a third-party entity to perform an audit pursuant to this
21 section.
22 Sec. 13. A utilization review agent shall not:
23 (1) Be compensated based on its volume of denials; or
24 (2) Base any incentive or penalty for a medical reviewer of such
25 agent based on the volume of denials such reviewer issues or upholds.
26 Sec. 14. For purposes of sections 14 to 16 of this act:
27 (1) Biomarker means a characteristic that is objectively measured
28 and evaluated as an indicator of normal biological processes, pathogenic
29 processes, or pharmacologic responses to a specific therapeutic
30 intervention, including known gene-drug interactions for medications
31 being considered for use or already being administered. Biomarkers
-10-

AM1187 AM1187
LB77 LB77
MLU - 04/25/2025 MLU - 04/25/2025
1 include, but are not limited to, gene mutations, characteristics of
2 genes, or protein expression;
3 (2) Biomarker testing means the analysis of tissue, blood, or other
4 biospecimen for the presence of a biomarker. Biomarker testing includes,
5 but is not limited to, single-analyte tests, multi-plex panel tests,
6 protein expression, and whole exome, whole genome, and whole
7 transcriptome sequencing;
8 (3) Clinical utility means sufficient medical and scientific
9 evidence indicating that the use of a biomarker test will provide
10 meaningful information that affects treatment decisions and guides
11 improvement of net health outcomes including an improved quality of life
12 or longer survival;
13 (4) Consensus statements means statements developed by an
14 independent, multidisciplinary panel of experts utilizing a transparent
15 methodology and reporting structure and with a conflict of interest
16 policy. These statements are aimed at specific clinical circumstances and
17 based on the best available evidence for the purpose of optimizing the
18 outcomes of clinical care;
19 (5) Health carrier has the same meaning as in section 44-1303; and
20 (6) Nationally recognized clinical practice guidelines means
21 evidence-based clinical practice guidelines developed by independent
22 organizations or medical professional societies utilizing a transparent
23 methodology and reporting structure and with a conflict of interest
24 policy. Clinical practice guidelines establish standards of care informed
25 by a systematic review of evidence and an assessment of the benefits and
26 risks of alternative care options and include recommendations intended to
27 optimize patient care.
28 Sec. 15. (1) On and after January 1, 2028, and notwithstanding
29 section 44-3,131, (a) any individual or group sickness and accident
30 insurance policy or subscriber contract delivered, issued for delivery,
31 or renewed in this state and any hospital, medical, or surgical expense-
-11-

AM1187 AM1187
LB77 LB77
MLU - 04/25/2025 MLU - 04/25/2025
1 incurred policy, except for policies that provide coverage for a
2 specified disease or other limited-benefit coverage and (b) any self-
3 funded employee benefit plan to the extent not preempted by federal law,
4 shall include coverage for biomarker testing pursuant to the criteria
5 established under subsection (2) of this section.
6 (2) Biomarker testing shall be covered when:
7 (a) The test is used for:
8 (i) The diagnosis, treatment, appropriate management, or ongoing
9 monitoring of cancer, an autoimmune or autoinflammatory disease,
10 Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease,
11 rheumatoid arthritis, preeclampsia, sickle cell anemia, or a
12 cardiovascular condition;
13 (ii) An organ or tissue transplant; or
14 (iii) Pharmacogenomic testing; and
15 (b) The test provides clinical utility as demonstrated by medical
16 and scientific evidence, including, but not limited to:
17 (i) Labeled indications for a test approved or cleared by the
18 federal Food and Drug Administration;
19 (ii) Indicated tests for a drug approved by the federal Food and
20 Drug Administration;
21 (iii) Warnings and precautions on drug labels approved by the
22 federal Food and Drug Administration;
23 (iv) National coverage determinations by the federal Centers for
24 Medicare and Medicaid Services or local coverage determinations by the
25 medicare administrative contractor; or
26 (v) Nationally recognized clinical practice guidelines and consensus
27 statements.
28 (3) Coverage, as specified in subsection (2) of this section, shall
29 be provided in a manner that limits disruptions in care, including the
30 need for multiple biopsies or biospecimen samples.
31 (4) The patient and prescribing practitioner shall have access to a
-12-

AM1187 AM1187
LB77 LB77
MLU - 04/25/2025 MLU - 04/25/2025
1 clear, readily accessible, and convenient process to request an exception
2 to a coverage policy. The process shall be made readily accessible on the
3 health carrier's website.
4 Sec. 16. (1) The medical assistance program shall cover biomarker
5 testing no later than January 1, 2028.
6 (2) Biomarker testing shall be covered when:
7 (a) The test is used for:
8 (i) The diagnosis, treatment, appropriate management, or ongoing
9 monitoring of cancer, an autoimmune or autoinflammatory disease,
10 Parkinsonâ€™s disease, amyotrophic lateral sclerosis, Alzheimer's disease,
11 rheumatoid arthritis, preeclampsia, sickle cell anemia, or a
12 cardiovascular condition;
13 (ii) An organ or tissue transplant; or
14 (iii) Pharmacogenomic testing; and
15 (b) The test provides clinical utility as demonstrated by medical
16 and scientific evidence, including, but not limited to:
17 (i) Labeled indications for a test approved or cleared by the
18 federal Food and Drug Administration;
19 (ii) Indicated tests for a drug approved by the federal Food and
20 Drug Administration;
21 (iii) Warnings and precautions on drug labels approved by the
22 federal Food and Drug Administration;
23 (iv) National coverage determinations by the federal Centers for
24 Medicare and Medicaid Services or local coverage determinations by the
25 medicare administrative contractor; or
26 (v) Nationally recognized clinical practice guidelines and consensus
27 statements.
28 (3) Coverage, as specified in subsection (2) of this section, shall
29 be provided in a manner that limits disruptions in care, including the
30 need for multiple biopsies or biospecimen samples.
31 (4) Entities contracting with the medical assistance program to
-13-

AM1187 AM1187
LB77 LB77
MLU - 04/25/2025 MLU - 04/25/2025
1 deliver services to program recipients shall provide biomarker testing at
2 the same scope, duration, and frequency as the medical assistance program
3 otherwise provides to recipients.
4 (5) The recipient and participating medical assistance program
5 provider shall have access to a clear, readily accessible, and convenient
6 process to request an exception to a coverage policy of the medical
7 assistance program. The process shall be made readily accessible on the
8 Department of Health and Human Services' website.
9 Sec. 17. Sections 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, and 13 of
10 this act become operative on January 1, 2026. The other sections of this
11 act become operative on their effective date.
12 Sec. 18. If any section in this act or any part of any section is
13 declared invalid or unconstitutional, the declaration shall not affect
14 the validity or constitutionality of the remaining portions.
-14-

[DELETED: yB1 S t o s a i t f nsScS 2  F p o t E T i PA( A d h t s m a i s4(0s1c2( C r c h t s m a i s344(5( E h c s m h c s6m7a8s9(041(2p3( G a h h t s m a i s475(6( H c p h t s m a i s747A7L5M]
[DELETED: ( H c s h t s m a i s4( H c h t s m a i s 4e(( N m c d e e ot(S P A t p m a s o o0m a s o a i w a e l f1a2(3o u r a m a d t a r4a5a6u r a r f r u t7a8( U h c s m a h c s w9r0E T i P A A f m 1n p a c i t o o a p2w3(4a5( S t e t s p t c b a6m w t c o t t i t s o t7u8( U r a h t s m a i s940S 3  ( A u r a s m p1a r a r i w c7A7L5M]
[DELETED: r c a o i w S rra s c c w i a d in t d t p a P arf(p a r o r o t a a er0(1i u t u r a w h b2u3(4o5r6S 4  ( A u r a s e t a7a8e9t a d m b m b a c p o t0r1( P a c a v n l i a U2S3(4a c g t t h c s b5r6(7o o t u r a m d w i8r f t p o h c s p t9e o N A s m d m b p0l1(7A7L5M]
[DELETED: oan s i t r f d c w cr(t m n t a o t e oi n o a h c s t e hc p s h t o t d t h cs w t p o c p w i r f0d a o t h c s u r T1e h c p m r t s d o2w t b d a r n o t a3d4d5c6( F a d u s ( o t7s8c p w t a d d r t9s0b d a t d u s ( o t1s f a u h c s o ( w t b2d3n4(5r6p7S8a a d f p a a r b 9p0( P a c a v u l i a U1S7A7L5M]
[DELETED: (he( T p m b c f t s os( T p t a e ( i ttt h c s a ( i s f t p td0c1( N h b d i i m t i a2d3(4a5(6u7r8t9o0t1S2a a s u p a r f f3p4u p a r f f a o h c5s6t p p i l T t l d n a t7i8p9a0p1(7A7L5M]
[DELETED: ( A h c p s u o t a up( E a p i s ( o t s au r a s a a p p ar( T s d n p a u r af u a p a m t u a Iwm i c w t u p a r0f1( A u r a m r f t d a2e3u4a p i p t 4 C 1 o5o e p a m t a a6s t p a p f p h c7p8n t h c p a l n d p t9i0o1S2r p a o a h c s t u3r4p5c6( F a p a r f u h c7s w s h a o a n8i9( F a p a r f n h c0s1m7A7L5M]
[DELETED: ( B J 1 2 i a u r ar p a o a h c s t urpc( F a p a r f u h cs w f h a o a ni( F a p a r f n h c0s1m2( N i t s p a h c p a3h c f c f s t f u t4p5p6o7( H c s a d a i a u8r9s0( I t n t t h c p t a p1a h b a t u r a s2i3p4S 8  N u r a s r p5a6(7( P t f t p o e8h9t0( S t h a r o A o B f t U S1P7A7L5M]
[DELETED: C o I P o t C f D CaaS 9  ( A u r a s n r lc o r a a p a i c ip w s d f t d t h c pr t p a a u t e w nl(0t c p r f a h c s p b t1h2(3t h c s o p m h i t p4a5p6(7d8( T h c p w n l c w t9p0(1a2(3t4( T h c p f t o p a5a b r h c s f w p6a7S8a s b v f a l o y f t d t9u0f a p d t h a t s o d1l7A7L5M]
[DELETED: y(g a h t p a s r v ft( I t h c p s a t r f tc o i c t u r a sr t t r p t t e o t ca( I a u r a f t r t a t0r1o2c3f4d5( N i t s s b i t p 6h7a8a9t h c s r t h c p a t0c1( T s d n r a h b p t c2c t o s f a h c t t t o3c4w5n6S 1  ( O r o i d a a7p8p a u r a s h t a p9a0a1a7A7L5M]
[DELETED: a(p a h c s t c i c oab( A u r a s c t h a pa i h g t a e w t e cha0S1b t s b o a u r a d t d2d o m h c s b i w o i p o3m4(5e6p w i a i a a u o7w8( T d m a a t a a u r9a a u m s T d m0c1s2S3(4( B a i o p f a m r o s5a6S7( B m a c t i o m8a9p o p r t a s t0i i k g i f m1b c f u o a b a B7A7L5M]
[DELETED: i b a n l t g m c og(bb i n l t s t m p tp e a w e w g a wt( C u m s m a se i t t u o a b t w p0m i t a t d a g1i2o3( C s m s d b a4i5m a r s a w a c o i6p7b8o9(0( N r c p g m1e c p g d b i2o3m a r s a w a c o i4p5b6r7o8S 1  ( O a a J 1 2 a n9s 4 ( a i o g s a a0i1o7A7L5M]
[DELETED: i p e f p t p c f s d o o l c a ( a sfs i c f b t p t t ce((( T d t a m o om o c a a o a d0P1r a p s c a o 2c3(4(5( T t p c u a d b m6a7( L i f a t a o c b t8f9( I t f a d a b t f F a0D1( W a p o d l a b t2f3( N c d b t f C f4M a M S o l c d b t5m6(7s8(9b0n1(7A7L5M]
[DELETED: cthSt((( T d t a m o om o c a a o a d0P1r a p s c a o 2c3(4(5( T t p c u a d b m6a7( L i f a t a o c b t8f9( I t f a d a b t f F a0D1( W a p o d l a b t2f3( N c d b t f C f4M a M S o l c d b t5m6(7s8(9b0n1( E c w t m a p t7A7L5M]
[DELETED: dto( T r a p m a ppp t r a e t a c p o t maDS0t1a2S3d i o u t d s n a4t7A7L5M]